trending Market Intelligence /marketintelligence/en/news-insights/trending/Zp6q5IvjiwyLVahjp94yTA2 content esgSubNav
In This List

Roche advances in I-O with Tecentriq data; US healthcare spending slows


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Roche advances in I-O with Tecentriq data; US healthcare spending slows

Here are the editors' top picks for the week ended Dec. 8.

Roche moves up a gear in lung cancer after 'encouraging' Tecentriq data

Roche Holding AG moved up a gear in immuno-oncology after reporting strong data in previously untreated lung cancer patients, potentially catapulting the company to the fore in one of the most competitive fields of research.

U.S. healthcare spending slows in wake of insurance expansion and drug cost bump

U.S. healthcare spending grew 4.3% in 2016, a slowdown from the two years prior as spikes in insurance enrollment and retail prescription drug costs plateaued, the Centers for Medicare and Medicaid Services found.

Sino Biopharm pads hepatitis market foothold in China with generic approval

The arrival of the generic version Qingzhong spells competition for originator Viread, which secured a spot on China's national reimbursement drug list in February.

GSK announces new £40M investment in UK genomics research

The Brentford, England-based pharmaceutical company is investing in an expansion of its previously announced genetic research alliance with UK Biobank.

NIH opioid partnership in motion, but lacks funding, industry commitment

The National Institutes of Health is close to moving a plan of action forward for a proposed public-private partnership, but the initiative lacks government funds and industry has yet to commit any cash, the head of the agency told lawmakers.

Valeant, J&J psoriasis drugs slated for updated price group review

With new plaque psoriasis options on the market from Valeant Pharmaceuticals International Inc. and Johnson & Johnson and more on the way, the Institute for Clinical and Economic Review will update last year's review of the drug class.

Capitol Checkup: Biopharmas debate patent system, industry image, pricing cures

Even though the Trump administration is filling up with officials who appear to be friendly to the biopharmaceutical industry, that circumstance is unlikely to cure the sector's image problem, CEOs from some of the top drug companies acknowledged.